EPIRUS Biopharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development, manufacturing and commercialization of biosimilar therapeutics. The Company’s pipeline of biosimilar product candidates includes BOW015, a biosimilar version of infliximab;BOW050, a biosimilar version of Humira (adalimumab), and BOW070, a biosimilar version of Actemra (tocilizumab). BOW050 (Adalimumab) and BOW070 (Tocilizumab) are in the preclinical stage of development. The Company’s lead product candidate is BOW015, which is indicated for the treatment of various inflammatory diseases, including rheumatoid arthritis, Crohn's Disease, ankylosing spondylitis, psoriatic arthritis and psoriasis.